Popular weight-loss drugs may play surprising role in cancer outcomes

Approximately 11 percent of adults in the U.S. utilize GLP-1 medications for weight loss. Recent findings suggest that GLP-1 drugs, including Ozempic and Wegovy, might reduce cancer risk by modifying the body's immune response. However, researchers emphasize that key clinical trials are still necessary to confirm these outcomes. The data highlights both the widespread adoption of these treatments and their potential surprising role in improving long-term health outcomes regarding cancer prevention and immune system alteration.